Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has assisted Novozymes Biopharma DK A/S
Mandate

Vinge has assisted Novozymes Biopharma DK A/S

November 08, 2011

Vinge has assisted Novozymes Biopharma DK A/S in the sale of Novozymes Biopharma Sweden AB to Repligen Corporation. Novozymes is the world leader in bio innovation with industrial enzymes, microorganisms, and biopharmaceutical ingredients as its business. Novozymes generated sales of DKK 9,724 million and EBIT of DKK 2,117 million in 2010.

Repligen Corporation is a leading supplier of critical technologies and ingredients used to manufacture biologic drugs. Repligen's corporate headquarters are in Massachusetts, USA.

Vinge’s team has primarily consisted of Björn Mullaart (partner), Karin Ebbinghaus (senior associate and Karin Engström (associate).

Related

Vinge advises Consolid Equity and other sellers on the sale of Sertion to Altor

 Vinge has advised Consolid Equity and other sellers on the sale of the Sertion Group to Altor. In connection with the transaction, entrepreneurs and management will reinvest and remain as key owners, partnering with Altor to accelerate the group’s next phase of growth across existing markets and into new geographies.
May 11, 2026

Vinge advises Stendörren in connection with issuance of green capital securities

 Vinge has advised Stendörren Fastigheter AB in connection with its issuance of green capital securities in an amount of SEK 400 million (within a framework of SEK 800 million).
May 07, 2026

Vinge advises Ingrid Capacity on its issuance of senior secured bonds in an amount of SEK 400 million

 Vinge has acted as legal counsel to Ingrid Capacity AB (publ) in connection with its issuance of senior secured bonds in an aggregate principal amount of SEK 400 million, issued under a total framework amount of SEK 1 billion.
May 07, 2026